ATE210439T1 - Verfahren und mittel zur inhibierung von proteinkinasen - Google Patents

Verfahren und mittel zur inhibierung von proteinkinasen

Info

Publication number
ATE210439T1
ATE210439T1 AT95941340T AT95941340T ATE210439T1 AT E210439 T1 ATE210439 T1 AT E210439T1 AT 95941340 T AT95941340 T AT 95941340T AT 95941340 T AT95941340 T AT 95941340T AT E210439 T1 ATE210439 T1 AT E210439T1
Authority
AT
Austria
Prior art keywords
independently represents
protein kinases
inhibiting protein
double bond
together represent
Prior art date
Application number
AT95941340T
Other languages
English (en)
Inventor
Neill A Giese
Nathalie Lokker
Original Assignee
Cor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cor Therapeutics Inc filed Critical Cor Therapeutics Inc
Application granted granted Critical
Publication of ATE210439T1 publication Critical patent/ATE210439T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
AT95941340T 1994-10-28 1995-10-26 Verfahren und mittel zur inhibierung von proteinkinasen ATE210439T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/332,597 US5795910A (en) 1994-10-28 1994-10-28 Method and compositions for inhibiting protein kinases
PCT/US1995/013882 WO1996013259A2 (en) 1994-10-28 1995-10-26 Method and compositions for inhibiting protein kinases

Publications (1)

Publication Number Publication Date
ATE210439T1 true ATE210439T1 (de) 2001-12-15

Family

ID=23298937

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95941340T ATE210439T1 (de) 1994-10-28 1995-10-26 Verfahren und mittel zur inhibierung von proteinkinasen

Country Status (14)

Country Link
US (3) US5795910A (de)
EP (1) EP0788356B9 (de)
JP (1) JPH10508024A (de)
KR (1) KR970706812A (de)
CN (1) CN1165481A (de)
AT (1) ATE210439T1 (de)
AU (1) AU706621B2 (de)
CA (1) CA2203757A1 (de)
DE (1) DE69524628T2 (de)
DK (1) DK0788356T3 (de)
ES (1) ES2170172T3 (de)
PT (1) PT788356E (de)
TW (1) TW467743B (de)
WO (1) WO1996013259A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699843B2 (en) * 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
CN1146747C (zh) * 1996-08-06 2004-04-21 精工爱普生株式会社 液晶显示装置和使用液晶显示装置的电子仪器
AU5675099A (en) * 1998-08-17 2000-03-06 William E. Trout Use of zeranol to modulate reproductive cycles
US20030219427A1 (en) * 1998-08-18 2003-11-27 Allen Hamish J. TPL-2/COT kinase and methods of use
BR9916879A (pt) * 1998-12-07 2001-11-06 Ecosmart Technologies Inc Composição e método para tratamento do câncer utilizando óleos essenciais vegetais naturais
US6635671B1 (en) 1998-12-24 2003-10-21 Novation Pharmaceuticals Inc. Compounds which affect mRNA stability and uses therefor
WO2001012210A1 (en) * 1999-08-13 2001-02-22 The Scripps Research Institute Methods and compositions useful for modulation of angiogenesis using tyrosine kinase raf and ras
GB9925958D0 (en) * 1999-11-02 1999-12-29 Bundred Nigel J Therapeutic use
US7087608B2 (en) * 2000-03-03 2006-08-08 Robert Charles Atkins Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
JP2004292314A (ja) * 2000-12-14 2004-10-21 Chugai Pharmaceut Co Ltd ケラチノサイト増殖抑制剤
US6565864B2 (en) 2000-12-28 2003-05-20 Unilever Home & Personal Care Usa, A Division Of Conopco, Inc. Skin care product containing retinoids and phytoestrogens in a dual compartment package
CN100456962C (zh) * 2001-02-09 2009-02-04 荷兰联合利华有限公司 含大豆蛋白和抑制素的食物制品
US7553979B2 (en) * 2001-11-09 2009-06-30 Conforma Therapeutics Corporation HSP90-inhibiting zearalanol compounds and methods of producing and using same
FR2835252B1 (fr) 2002-01-25 2005-08-05 Seppic Sa Utilisation d'un compose inactivant la proteine kinase a dans une composition contenant un milieu cosmetiquement acceptable, pour eclaicir la peau
ES2555307T3 (es) * 2002-03-08 2015-12-30 Eisai R&D Management Co., Ltd. Compuestos macrocíclicos útiles como agentes farmacéuticos
US7915306B2 (en) * 2002-03-08 2011-03-29 Eisai Co., Ltd. Macrocyclic compounds useful as pharmaceuticals
WO2003086334A1 (fr) * 2002-04-17 2003-10-23 Taisho Pharmaceutical Co., Ltd. Produit tonique pour la pousse de cheveux
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
EP1608338A1 (de) * 2003-04-02 2005-12-28 Celator Technologies Inc. Pharmazeutische zusammensetzungen enthaltend wirkstoffe mit einer lactongruppe und übergangsmetallionen
ES2388138T3 (es) 2003-08-27 2012-10-09 Ophthotech Corporation Terapia de combinación para tratamiento de trastornos neovasculares oculares
EP1794137A4 (de) 2004-09-27 2009-12-02 Kosan Biosciences Inc Spezifische kinase-hemmer
JP2009521493A (ja) * 2005-12-23 2009-06-04 アルコン，インコーポレイテッド 眼への受容体チロシンキナーゼ阻害（ＲＴＫｉ）化合物の送達のための医薬製剤
US7601852B2 (en) * 2006-05-11 2009-10-13 Kosan Biosciences Incorporated Macrocyclic kinase inhibitors
CN103539769B (zh) * 2006-08-11 2016-03-16 斯特拉斯堡大学 用作激酶抑制剂和hsp90抑制剂的大环化合物
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
CN101778627B (zh) * 2007-07-25 2016-04-13 卫材R&D管理株式会社 用于治疗癌症的多激酶抑制剂
JP5564431B2 (ja) 2007-10-29 2014-07-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 ゼアラレノンアナログ化合物ががんを処置する能力を予測する方法
EP2231634B1 (de) 2007-12-07 2016-05-11 Eisai R&D Management Co., Ltd. Zwischenprodukte bei der synthese von zearalenon-makrolid-analoga
US20110190237A1 (en) * 2008-01-15 2011-08-04 Nexgenix Pharmaceuticals Macrocyclic Prodrug Compounds Useful as Therapeutics
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US8642834B2 (en) 2009-02-27 2014-02-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
CN101928700B (zh) * 2009-07-28 2012-05-02 北京恒宇视野生物科技有限公司 蛋白激酶pftk1单克隆抗体及其制备方法
WO2012021974A1 (en) * 2010-08-20 2012-02-23 The Hospital For Sick Children Compositions and methods for treatment of cystic fibrosis and diseases associated with aberrant protein cellular processing
EP2702173A1 (de) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Verwendung von emt-gensignaturen bei der entdeckung von krebswirkstoffen, -diagnostika und -behandlungen
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US10434085B2 (en) 2015-06-04 2019-10-08 University Of North Carolina At Greensboro Non-aromatic difluoro analogues of resorcylic acid lactones

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3196019A (en) * 1964-04-06 1965-07-20 Purdue Research Foundation Anabolic and estrogenic compound and process of making
JPS6239558A (ja) * 1985-08-13 1987-02-20 Kanegafuchi Chem Ind Co Ltd α−シアノアクリル酸アミド誘導体
JPS6239523A (ja) * 1985-08-14 1987-02-20 Kanegafuchi Chem Ind Co Ltd 酵素阻害剤
JPS6242923A (ja) * 1985-08-19 1987-02-24 Kanegafuchi Chem Ind Co Ltd 酵素阻害剤
JPS6242925A (ja) * 1985-08-20 1987-02-24 Kanegafuchi Chem Ind Co Ltd 酵素阻害剤
US4842862A (en) * 1986-07-03 1989-06-27 International Minerals & Chemical Corp. Immunostimulating agents
GB9225396D0 (en) * 1992-12-04 1993-01-27 Sandoz Ltd Improvements in or relating to organic compounds

Also Published As

Publication number Publication date
DE69524628T2 (de) 2002-08-08
WO1996013259A3 (en) 1996-08-01
CA2203757A1 (en) 1996-05-09
AU706621B2 (en) 1999-06-17
US5795910A (en) 1998-08-18
MX9703113A (es) 1998-06-30
AU4278996A (en) 1996-05-23
DE69524628D1 (de) 2002-01-24
JPH10508024A (ja) 1998-08-04
CN1165481A (zh) 1997-11-19
WO1996013259A2 (en) 1996-05-09
ES2170172T3 (es) 2002-08-01
EP0788356A2 (de) 1997-08-13
DK0788356T3 (da) 2002-03-18
TW467743B (en) 2001-12-11
PT788356E (pt) 2002-06-28
EP0788356B9 (de) 2002-10-02
US5728726A (en) 1998-03-17
KR970706812A (ko) 1997-12-01
EP0788356B1 (de) 2001-12-12
US5674892A (en) 1997-10-07

Similar Documents

Publication Publication Date Title
DE69524628D1 (de) Verfahren und mittel zur inhibierung von proteinkinasen
TR199902406T2 (xx) Kristalli cefdinir amin tuz.
GEP20063830B (en) Nogo Receptor-Mediated Blockade of Axonal Growth
FI960089A0 (fi) Proteiinikinaasi C:n oligonukleotidimodulaatio
DE69524365T2 (de) Verfahren zur Isolierung und Reinigung von 2'-Deoxy-2',2'-difluornucleosiden
DE69603240D1 (de) Neue deazapurinderivate; eine neue klasse von crf1-spezifischen liganden
DE69434955D1 (de) Aryliden und Heteroaryliden-oxindolderivate als Tyrosin Kinase Inhibitoren
PT1083903E (pt) Indenopirrolocarbazoles em ponte
DE3854003D1 (de) Verfahren zur Herstellung von N-substituiertem Amin.
DK0638068T3 (da) Fremgangsmåde til fremstilling af (S)-3-amino-1-substitueret-pyrrolidiner
DE69416518T2 (de) Neue 9-n-bicyclische nucleosidverbindungen nützlich als selektive inhibitoren von proinflammatorische cytokinen
DE59510180D1 (de) Verfahren zur Herstellung von 4-Amino-2,2,6,6-tetramethyl-piperidin
DE69330977D1 (de) Verfahren zur Herstellung von Hydroxylfunktionen enthaltenden Derivaten von epoxidierten Dien-Blockcopolymeren
DE69505868T2 (de) Verfahren zur Anwendung von Amino-Silizium Verbindungen zur selektiven Gastrennung
FI944563A (fi) Mikro-organismeja, valmistusmenetelmä ja käyttö
DE69408394D1 (de) 4-Piperidino-piperidin zur Behandlung von Tumoren
DE69812395D1 (de) Verfahren zur synthese von taxanen
DE69617685T2 (de) Zusammensetzung und verfahren zur stabilisierung von radiomarkierten organischen verbindungen
ATE41662T1 (de) Derivate von dihydro-1h-pyrrolo(1,2-c>imidazol3,5-dion zur aktivierung des wahrnehmungsvermoegens.
DE69715668T2 (de) N-(pyridinylamino)isoindoline und verwandte verbindungen
ATE496939T1 (de) Methode zur reinigung von keratinozyten- wachstumfaktoren
ATE82124T1 (de) Anwendung von n-(2-(diaethylamino)aethyl>-2-methoxy-4((1-h-4,5ihydro-2-imidazolyl)amino>-5- chlorobenzamid als anxiolytisches und antipsychotisches mittel.
DE69425405T2 (de) Verbessertes Verfahren zur Herstellung von 2,4-di(alkylamine)-6-alkylthio-s-Triazinen und 2,4-alkylamine-4,6-di(alkylthio)-s-Triazinen
DE69602220T2 (de) Verfahren zur Verbesserung der thermischen Stabilität von Sepiolith
DE69308102D1 (de) Verfahren zur Verbesserung der Kompatibilität der Oberfläche des Polypropylens, und damit hergestellte Zusammensetzungen und Artikel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee